Physical radiofrequency adjuvant enhances immune responses to influenza H5N1 vaccination.
Physical radiofrequency adjuvant enhances immune responses to influenza H5N1 vaccination.
复制标题
DOI：
10.1096/fj.202101703r
复制
发表时间：
2022-03
期刊：
影响因子：
--
通讯作者：
Chen X
中科院分区：
文献类型：
--
作者：
Li Z;Kim KH;Bhatnagar N;Park BR;Jeeva S;Jung YJ;Raha J;Kang SM;Chen X
流行前H5N1流感疫苗的免疫原性相对较低，往往需要高抗原量和两次免疫才能诱导保护性免疫。疫苗佐剂的加入有望在大流行爆发期间延长疫苗剂量。本研究提出了一种物理射频佐剂（RFA），可以在不修改疫苗制剂的情况下方便有效地提高H5N1疫苗的免疫原性和功效。物理 RFA 是基于对皮肤进行短暂的射频治疗，以诱导热应激，从而增强皮内疫苗诱导的免疫反应，同时将局部或全身不良反应降至最低。我们发现物理 RFA 可以显着增加小鼠模型中 H5N1 疫苗诱导的血凝抑制抗体滴度。在 RFA 存在下皮内 H5N1 疫苗（而非单独的疫苗）显着降低了肺部病毒滴度，减少了体重减轻，并提高了致命病毒攻击后的存活率。 RFA 存在下保护作用的改善与雄性和雌性小鼠对 H5N1 疫苗接种的体液和细胞免疫反应增强相关，表明 RFA 效应在小鼠模型中没有性别差异。我们的数据支持进一步开发物理 RFA，以方便地增强 H5N1 疫苗的功效。
Pre-pandemic influenza H5N1 vaccine has relatively low immunogenicity and often requires high antigen amounts and two immunizations to induce protective immunity. Incorporation of vaccine adjuvants is promising to stretch vaccine doses during pandemic outbreaks. This study presents a physical radiofrequency (RF) adjuvant (RFA) to conveniently and effectively increase the immunogenicity and efficacy of H5N1 vaccine without modification of vaccine preparation. Physical RFA is based on a brief RF treatment of the skin to induce thermal stress to enhance intradermal vaccine-induced immune responses with minimal local or systemic adverse reactions. We found that physical RFA could significantly increase H5N1 vaccine-induced hemagglutination inhibition antibody titers in murine models. Intradermal H5N1 vaccine in the presence of RFA but not vaccine alone significantly lowered lung viral titers, reduced body weight loss, and improved survival rates after lethal viral challenges. The improved protection in the presence of RFA was correlated with enhanced humoral and cellular immune responses to H5N1 vaccination in both male and female mice, indicating no gender difference of RFA effects in murine models. Our data support further development of the physical RFA to conveniently enhance the efficacy of H5N1 vaccine.